Abstract 14459: Daily Coffe Consumption Does Not Impact All-Cause or Specific Cardiovascular Mortality: Findings from the National Health and Nutrition Examination Survey
Studies have examined the association between the consumption of caffeinated coffee to all cause, and cardiovascular (CV), mortality. This study aimed to delineate this using data from the National Health and Nutrition Examination Survey (NHANES) III and its subsequent follow up data. It was hypothesized that coffee consumption would not offer a decrease in all cause or cv mortality. Patients were included in the study if all of the following criteria were met: 1) follow up mortality data was available, 2) age of at least 45 years old, 3) reported amount of average coffee consumption. A total of 8,608 patients were included, with patients stratified into following groups of average daily coffee consumption: 1) no coffee consumption, 2) less than 1 cup, 3) 1 cup, 4) 2-3 cups, 5) 4-5 cups, 6) more than 6 cups. All-cause mortality, ischemia related mortality, congestive heart failure related mortality, and stroke related mortality. Baseline characteristics were compared using t-tests and Mann-Whitney U tests. Odds-ratios, 95% confidence intervals, and p-values were calculated for univariate analysis, using the no coffee consumption group as reference. These were then adjusted for race, gender, body mass index, systolic blood pressure, current smoking status, history of diabetes, total cholesterol, LDL, and HDL for a multivariate analysis. P-values of less than 0.05 were considered statistically significant. Table 1 outlines the results of the study. Both univariate and multivariate analysis results are reported. Asterisks denote a statistically significant finding. Univariate analysis demonstrated an association between coffee consumption and mortality, although most of this became insignificant on multivariate analysis. Coffee consumption does not impact all cause mortality or specific cv mortality. Strengths of this study include using a nationally representative sample while limitations include only limited follow up data beyond mortality.
- © 2012 by American Heart Association, Inc.